Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

After Consent Decree, Wockhardt May Sell US Site Amid Wider Revamp

Executive Summary

Wockhardt’s US arm Morton Grove Pharmaceuticals, which is bound by a consent decree of permanent injunction, discontinues production to undertake an “orderly closure” and potential sale of its Illinois site. Indian parent firm taps contract manufacturers to service US market.

You may also be interested in...



Why India Pharma Failed To Impress In 2020-22 Bull Run

Most Indian pharma stocks, including large firms, yielded double digit negative returns over the last 12 months while the overall market (Bombay Stock Exchange Sensex) delivered positive returns, a new study by an investment banking and consulting services firm indicates. The prognosis for fiscal years 2023/24, though, is optimistic.

Wockhardt’s Illinois Drug Firm Closed In FDA Settlement After GMP Problems Found Since 2011

Permanent injunction states Morton Grove Pharmaceuticals intends to sell its facility. Complaint comes more than 10 years after first of five inspections found GMP problems.

Tough Q1 In US For Glenmark, Eyes on Ryaltris Debut, Flovent Rival Filing

Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel